SASS6 promotes tumor proliferation and is associated with TP53 and immune infiltration in lung adenocarcinoma

被引：0

作者：

Li, Zihao ^{[1
]}

He, Lingyun ^{[1
]}

Li, Jiayi ^{[2
]}

Qian, Jing ^{[3
]}

Wu, Zuotao ^{[3
]}

Zhu, Yongjie ^{[3
]}

Zhuo, Ting ^{[4
]}

Nong, Jusen ^{[5
]}

Liang, Honghua ^{[1
]}

Zheng, Hua ^{[1
]}

Huang, Weijia ^{[1
]}

Huang, Julu ^{[6
]}

Cao, Jianbin ^{[1
]}

机构：

[1] Guangxi Med Univ, Liuzhou Peoples Hosp, Dept Thorac Surg, Liuzhou, Guangxi, Peoples R China

[2] Guangxi Med Univ, Liuzhou Peoples Hosp, Dept Nephrol, Liuzhou, Guangxi, Peoples R China

[3] Guangxi Med Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, Nanning, Guangxi, Peoples R China

[4] Guangxi Med Univ, Affiliated Hosp 1, Dept Resp Med, Nanning, Guangxi, Peoples R China

[5] Guangxi Med Univ, Affiliated Hosp 1, Dept Pediat Surg, Nanning, Guangxi, Peoples R China

[6] Guangxi Med Univ, Liuzhou Peoples Hosp, Dept Med Oncol, Liuzhou, Guangxi, Peoples R China

来源：

CLINICAL AND EXPERIMENTAL MEDICINE | 2024年 / 24卷 / 01期

关键词：

Cell cycle; Immune infiltration; Lung adenocarcinoma; Prognosis; SASS6; CENTROSOME AMPLIFICATION; CHROMOSOME INSTABILITY; CANCER; AFATINIB; ABNORMALITIES; GEFITINIB; ERLOTINIB; MUTATION; CERNA; CELLS;

D O I：

10.1007/s10238-024-01510-0

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The most common type of non-small cell lung cancer is lung adenocarcinoma (LUAD), which is characterized by high morbidity and poor survival. Up-regulation of SASS6 expression can lead to the progression of various malignant tumors. However, there are no relevant studies on the role of SASS6 in LUAD. SASS6 was highly expressed in most tumors, reflecting a good diagnostic value, and its overexpression in LUAD indicated discouraging overall prognosis. Functional enrichment analysis suggested that SASS6 was associated with cell cycle in LUAD. In addition, patients with high SASS6 expression had worse immune infiltration, but higher TMB and immune checkpoint, and higher sensitivity to multiple targeted drugs such as osimertinib. Cell experiments confirmed that knockdown of SASS6 could inhibit the viability of tumor cells.SASS6 has important value in the diagnosis of cancer. In particular, SASS6 is a crucial factor in the progression of LUAD, and has important clinical value, especially in the diagnosis, prognosis and treatment

引用

页数：16

共 50 条

[1] SASS6 Promotes Proliferation of Esophageal Squamous Carcinoma Cells by Inhibiting the p53 Signaling Pathway
Chen, Y.
Zhu, K.
Chen, J. Q.
Xu, Y.
Lin, L.
Huang, Z.
Zhang, J.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E614 - E614
[2] SASS6 promotes proliferation of esophageal squamous carcinoma cells by inhibiting the p53 signaling pathway
Xu, Yuanji
Zhu, Kunshou
Chen, Junqiang
Lin, Liyan
Huang, Zhengrong
Zhang, Jiulong
Chen, Yuanmei
CARCINOGENESIS, 2021, 42 (02) : 254 - 262
[3] Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma
Wu, Chengde
Rao, Xiang
Lin, Wei
CANCER MEDICINE, 2021, 10 (03): : 806 - 823
[4] Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
Sun, Hao
Liu, Si-Yang
Zhou, Jia-Ying
Xu, Jin-Tian
Zhang, Huang-Kai
Yan, Hong-Hong
Huan, Jiao-Jiao
Dai, Ping-Ping
Xu, Chong-Rui
Su, Jian
Guan, Yan-Fang
Yi, Xin
Yu, Rong-Shan
Zhong, Wen-Zhao
Wu, Yi-Long
EBIOMEDICINE, 2020, 60
[5] A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with TP53 mutation
Fu, Jing
Li, Yaonan
Li, Cuidan
Tong, Yuyang
Li, Mengyuan
Cang, Shundong
TRANSLATIONAL CANCER RESEARCH, 2021, 10 (09) : 3963 - +
[6] Intronic TP53 Polymorphisms Are Associated with Increased Δ133TP53 Transcript, Immune Infiltration and Cancer Risk
Eiholzer, Ramona A.
Mehta, Sunali
Kazantseva, Marina
Drummond, Catherine J.
McKinney, Cushla
Young, Katie
Slater, David
Morten, Brianna C.
Avery-Kiejda, Kelly A.
Lasham, Annette
Fleming, Nicholas
Morrin, Helen R.
Reader, Karen
Royds, Janice A.
Landmann, Michael
Petrich, Simone
Reddel, Roger
Huschtscha, Lily
Taha, Ahmad
Hung, Noelyn A.
Slatter, Tania L.
Braithwaite, Antony W.
CANCERS, 2020, 12 (09) : 1 - 18
[7] Rare germline TP53 variants in lung adenocarcinoma
Parry, Erin Michelle
Gable, Dustin L.
Stanley, Susan E.
Armanios, Mary Y.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[8] Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma
Schabath, M. B.
Welsh, E. A.
Fulp, W. J.
Chen, L.
Teer, J. K.
Thompson, Z. J.
Engel, B. E.
Xie, M.
Berglund, A. E.
Creelan, B. C.
Antonia, S. J.
Gray, J. E.
Eschrich, S. A.
Chen, D-T
Cress, W. D.
Haura, E. B.
Beg, A. A.
ONCOGENE, 2016, 35 (24) : 3209 - 3216
[9] Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma
M B Schabath
E A Welsh
W J Fulp
L Chen
J K Teer
Z J Thompson
B E Engel
M Xie
A E Berglund
B C Creelan
S J Antonia
J E Gray
S A Eschrich
D-T Chen
W D Cress
E B Haura
A A Beg
Oncogene, 2016, 35 : 3209 - 3216
[10] MAZ promotes tumor proliferation and immune evasion in lung adenocarcinoma
Chen, Yan
Zhu, Xinsheng
Wang, Jue
Hu, Junjie
Zhang, Jing
Zhang, Xun
Han, Lu
Yu, Huansha
Hu, Haiyang
Fei, Ke
Zhang, Peng
Zhang, Lele
ONCOGENE, 2024, 43 (50) : 3619 - 3632

← 1 2 3 4 5 →